Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

Παρόμοια τεκμήρια

• Safety and Feasibility of Chimeric Antigen Receptor T Cell Therapy after Allogeneic Hematopoietic Cell Transplantation in Relapsed/ Refractory B Cell Non-Hodgkin’s Lymphoma
  ανά: Jain, Tania, κ.ά.
  Έκδοση: (2019)
• THE INTERNATIONAL PROGNOSTIC INDEX IS ASSOCIATED WITH OUTCOMES IN DIFFUSE LARGE B CELL LYMPHOMA AFTER CAR T CELL THERAPY
  ανά: Garcia-Recio, Marta, κ.ά.
  Έκδοση: (2020)
• DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
  ανά: Wudhikarn, Kitsada, κ.ά.
  Έκδοση: (2020)
• Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
  ανά: Pennisi, Martina, κ.ά.
  Έκδοση: (2020)
• Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
  ανά: Wudhikarn, Kitsada, κ.ά.
  Έκδοση: (2020)